Analytical Data
-
Gene name
CCL23
- Application
-
Alternative Names
CCL23；MIP3；MPIF1；SCYA23；C-C motif chemokine 23
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P55773
-
Expression Region
22-120aa
-
AA Sequence
RVTKDAETEF MMSKLPLENP VLLDRFHATS ADCCISYTPR SIPCSLLESY FETNSECSKP GVIFLTKKGR RFCANPSDKQ VQVCMRMLKL DTRIKTRKN
-
Molecular Weight
11.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CCL23, also known as chemokine (C-C motif) ligand 23, is a member of the CC chemokine family and plays a critical role in immune responses, particularly in the recruitment and activation of various immune cells. It is primarily secreted by activated monocytes, macrophages, and dendritic cells, and has been implicated in the pathogenesis of several inflammatory diseases and conditions, including rheumatoid arthritis, atherosclerosis, and cancer. Recent studies have highlighted its potential as a therapeutic target and biomarker due to its involvement in pathological processes, including tumor progression and metastasis. The research on recombinant CCL23 protein focuses on its structural characteristics, functional properties, and mechanisms of action within the immune system. By producing recombinant CCL23, scientists aim to explore its biological activities in vitro and in vivo, providing insights into its role in immune modulation. Such studies may advance our understanding of CCL23's involvement in disease mechanisms and pave the way for developing novel therapeutic strategies that utilize CCL23 as a target for intervention in various diseases. Additionally, the production of recombinant CCL23 can facilitate its application in preclinical models, helping to evaluate its potential as a drug candidate or as part of immunotherapy approaches. Therefore, the ongoing research into CCL23 not only deepens our understanding of chemokine biology but also holds promise for innovative treatments in the field of immunology.
